LOGIN  |  REGISTER
Assertio
Astria Therapeutics

Becton Dickinson to Announce Fiscal 2023 Fourth Quarter and Full Year Financial Results

October 12, 2023 | Last Trade: US$234.68 5.67 -2.36

FRANKLIN LAKES, N.J., Oct. 12, 2023 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that it will report its fiscal 2023 fourth quarter and full year financial results on Thursday, November 9, 2023. A news release will be issued at approximately 6:30 a.m. Eastern Time (ET) and will be available at www.bd.com/investors, along with related presentation materials. The news release and presentation materials will include summary financial information for the company's fiscal 2023 fourth quarter and full year financial results, which ended on Saturday, September 30, 2023. 

BD management will host an audio webcast at 8 a.m. ET on November 9, 2023 to discuss its financial results and provide an update on its operations and strategy. The audio webcast can be accessed at BD's investor relations website at www.bd.com/investors and a replay will be available shortly after the call at the same website.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 77,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

Contacts:

Media:       

Investors:

Troy Kirkpatrick                           

Adam Reiffe

VP, Public Relations                 

Sr. Director, Investor Relations

858.617.2361                               

201.847.6927           

This email address is being protected from spambots. You need JavaScript enabled to view it.              

This email address is being protected from spambots. You need JavaScript enabled to view it.  

Surmodics

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB